Krensavage Asset Management portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Krensavage Asset Management reported a $263M portfolio of 18 positions to the SEC as of the end of Q2 2026. Its largest positions are ENTA, JAZZ, UTHR. During the quarter it exited Indivior Pharmaceuticals and Alkermes plc..
Sections with a free account
What changed this quarter
8 positions with a change (4 added to, 2 trimmed, 2 sold). 5 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Abbott Laboratories+3,900%more sharesIncreased0.2% → 6.9%
- Indivior Pharmaceuticals−3.9 ppof portfolioSold out4.0% → —
- United Therapeutics−18%fewer sharesReduced19.5% → 14.3%
- Alkermes plc.−1.4 ppof portfolioSold out1.5% → —
- Exelixis−11%fewer sharesReduced7.0% → 7.7%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Enanta PharmaceuticalsENTA15.9%
- Jazz PharmaceuticalsJAZZ15.4%
- United TherapeuticsUTHR14.3%
- BioMarin PharmaceuticalBMRN11.4%
- ExelixisEXEL7.7%
- Abbott LaboratoriesABT6.9%
- SanofiSNY5.3%
- Indivior PharmaceuticalsSUPN5.0%
- Ultragenyx PharmaceuticalRARE5.0%
- Vanda PharmaceuticalsVNDA2.7%
- BioNTechBNTX2.1%
- GSKGSK1.9%
- BiogenBIIB1.6%
- Regeneron PharmaceuticalsREGN1.4%
- EmbectaEMBC1.4%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 18
Q2 2026: 89%
Q2 2026: 8.6%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
13F filings with amendments or confidential positions
- 13F Q4 2024 ↗filed Feb 18, 2025Amendment of Feb 18, 2025 (replaces the original) ↗
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Mar 25, 2026 (high confidence).
The data, as reported: KRENSAVAGE ASSET MANAGEMENT, LLC (CRD 168976): 7.B private funds: 1 hedge (gross assets $285M); 5.D assets by client type: pooled vehicles 100% (of $300M)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Dalal StreetInvestment firm · $327M
- MuhlenkampInvestment firm · $345M
- Matthew 25 ManagementInvestment firm · $345M
- Stonehill Capital ManagementInvestment firm · $350M
- SW Investment ManagementInvestment firm · $352M
- INCA InvestmentsInvestment firm · $353M